|
| 尿囊素铝预防非甾体类抗炎药相关性溃疡疗效观察 |
| Analysis of the Efficacy of Aldioxa Preventing Non steroidal Anti inflammatory Drugs Induced Peptic Ulcer |
| 投稿时间：2012-03-28 修订日期：2012-05-23 |
| DOI： |
| 中文关键词: 尿囊素铝 雷贝拉唑 非甾体类抗炎药相关性溃疡 |
| 英文关键词:Aldioxa Rabeprazole Non steroidal anti inflammatory drugs Ulcer Curative effect |
| 基金项目:丽水市科学技术局/丽水市卫生局丽水市第二批医学重点建设学科科技项目（编号：2010-011） |
|
| 摘要点击次数: 1140 |
| 全文下载次数: 1535 |
| 中文摘要: |
| 摘 要 目的：探讨尿囊素铝片预防非甾体类抗炎药（NSAIDs）相关性溃疡的临床疗效及安全性。方法：107例患者按随机数字表分为尿囊素铝组53例（予尿囊素铝片0.1 g， tid），雷贝拉唑组54例（予雷贝拉唑肠溶胶囊20 mg， qd），疗程均8周，观察两组临床疗效和不良反应。结果：用药8周末，尿囊素铝组消化性溃疡发生率5.66%，雷贝拉唑组消化性溃疡发生率7.41%，差异无统计学意义(P＞0.05)；两组药物不良反应发生率分别为3.77%和5.56%，差异也无统计学意义(P＞0.05)。而尿囊素铝组药物费用显著低于雷贝拉唑组，差异有统计学意义(P＜0.05)。结论：尿囊素铝预防NSAIDs相关性溃疡安全、有效、经济，值得临床使用。 |
| 英文摘要: |
| ABSTRACT Objective:To discuss the efficacy and safety of the prevention of aldioxa tablets of non-steroidal anti-inflammatory drugs (NSAIDs) induced peptic ulcer. Methods:107 eligible patients were randomly divided into aldioxa group (53 cases,0.1g each time, three times a day orally ) and rabeprazole group (54 cases, 20mg each time, once a day orally). The courses of the treatment of both groups were 8 weeks. The clinical efficacy and safety of two drugs were observed. Results:The morbidity of peptic ulcer of the aldioxa group was 5.66% after 8 weeks, while the rabeprazole group was 7.44%. There were no significant differences between the two groups (P>0.05). The incidences of ADR of the aldioxa group and rabeprazole group were 3.77% and 5.56%(P>0.05). The difference between the two groups had no statistical significance. The cost of the aldioxa group was significantly lower than that of the rabeprazole group（P＜0.05）. Conclusion:Aldioxa was an economic, safe, effective drug in the prevention of NSAIDs induced ulcer drugs and worthy of clinical application. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
